Skip To Content

Study ID: Vertex VX15-440-101 NextGen CFTR Correctors Phase 2 Proof of Concept (POC) study

Title:

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis

Location:
Sioux Falls Region
Principal Investigator:
James Wallace, MD
Disease:
Lung
Stage:
Phase II
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.